Research Articles
Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug Interactions

https://doi.org/10.1021/js980029pGet rights and content

Abstract

Amprenavir (141W94, VX-478, KVX-478) is metabolized primarily by CYP3A4 (cytochrome P450 3A4) in recombinant systems and human liver microsomes (HLM). The effects of ketoconazole, terfenadine, astemizole, rifampicin, methadone, and rifabutin upon amprenavir metabolism were examined in vitro using HLM. Ketoconazole, terfenadine, and astemizole were observed to inhibit amprenavir depletion, consistent with their known specificity for CYP3A4. The HIV protease inhibitors, indinavir, saquinavir, ritonavir, and nelfinavir, were included in incubations containing amprenavir to examine the interactions of HIV protease inhibitors in vitro. The order of amprenavir metabolism inhibition in human liver microsomes was observed to be: ritonavir > indinavir > nelfinavir > saquinavir. The K value for amprenavir-mediated inhibition of testosterone hydroxylation in human liver microsomes was found to be approximately 0.5 μM. Studies suggest that amprenavir inhibits CYP3A4 to a greater extent than saquinavir, and to a much lesser extent than ritonavir. Amprenavir, nelfinavir, and indinavir appear to inhibit CYP3A4 to a moderate extent, suggesting a selected number of coadministration restrictions.

References and Notes (28)

  • G. Cameron et al.

    The advanced HIV ritonavir study group. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections

    (1996)
  • J. Leonard et al.

    Prolongation of life and prevention of AIDS in advanced immunodeficiency with ritonavir

    Presented at the 3rd Conference on Retroviruses and Opportunistic Infections

    (1996)
  • R.M. Gulick et al.

    Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

    New Eng. J. Med.

    (1997)
  • A.S. Fauci et al.

    Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents

    Fed. Regist.

    (1996)
  • M. Battegay et al.

    Swiss HIV cohort study

    A pilot study of saquinavir in combination with ritonavir and d4T in patients with advanced HIV disease. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy

    (1997)
  • D. Batisse et al.

    Efficacy and safety of ritonavir and saquinavir in combination in protease inhibitor-experienced patients

    Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy

    (1997)
  • S. Deeks et al.

    Virologic effect of ritonavir plus saquinavir in subjects who have failed indinavir

    Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy

    (1997)
  • D.J. Livingston et al.

    Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy

    J. Infect. Dis.

    (1996)
  • S.D. Studenberg et al.

    Pharmacokinetics, excretion, and mass balance studies in dogs with 14C- 141W94 (VX-478), an HIV-1 protease inhibitor

    International Society for the study of Xenobiotics (ISSX) Proceedings

    (1996)
  • M. Barry et al.

    Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

    Clin. Pharmacokinet

    (1997)
  • G.N. Kumar et al.

    Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes

    J. Pharmacol. Therapeut.

    (1996)
  • G. Farrar et al.

    Prediction of potential drug interactions of saquinavir from in vitro data

    Proceedings of the BPS12–13

    (1994)
  • M.E. Fitzsimmons et al.

    Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome CYP3A4. Potential contribution to high first-pass metabolism

    Drug Metab. Dispos

    (1997)
  • V.A. Eagling et al.

    Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

    Br. J. Clin. Pharmacol.

    (1997)
  • Cited by (110)

    • Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings

      2017, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      Therefore, the slight exposure decrease (23%-24%) in etoposide and saquinavir when co-administered with grapefruit juice (100 mL single dose) and quercetin (500 mg 3 times daily for 8 days), respectively, could be caused by intestinal inhibition of OATPs. It should be noted that intestinal inhibition of CYP3A by grapefruit juice and quercetin could not be ruled out, based on the observations that both etoposide and saquinavir are substrates of CYP3A in vitro.110,149-170 Interestingly, quercetin also induced CYP3A, with a 24% reduction in exposure of co-administered midazolam, a CYP3A probe substrate,171 likely through pregnane X receptor activation.172

    • Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake

      2016, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      Therefore, the metabolic intrinsic Cl of HIV PI was measured in pooled liver microsomes (Table 6). In general, our metabolic data were consistent with previously published metabolic Cl values determined in human microsomes with a maximum fivefold difference for DRV.47-50 This discrepancy as well as other small deviations from our data may result from differences in methodology or the lack of correction for nonspecific binding in some studies.

    • Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir

      2012, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      It is responsible for oxidative biotransformation of more than 50% of drugs in humans and rats.6 SQV is metabolized primarily by CYP3A4 to mono- and dihydroxylated metabolites with negligible antiviral activity in humans.7–9 Mean Cmax (maximum concentration in body) and AUC (area under the curve) values were significantly elevated when SQV hard-gel formulation was coadministered with other CYP3A4 inhibitors, that is, ritonavir or indinavir.10,11

    View all citing articles on Scopus
    View full text